Get started
Author

Edmund Folefac

A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2023 · Elizabeth Pan, Wanling Xie, et al. · Molecular Cancer Therapeutics · 50
PDF
A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
2025 · Rana R. McKay, Wanling Xie, et al. · Journal of Clinical Oncology · 6
PDF
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
2023 · Chinmay Jani, Wanling Xie, et al. · Journal of Clinical Oncology · 2
PDF
Supplementary Table S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Figure 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Table 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Table S4 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Figure S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Data from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Table 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Table S2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Table S1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Figure 3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Figure S2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Figure 4 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Figure S1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Figure 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al. · Cancer Research Communications
Real-World Survival Outcomes and Risk Prediction Model in Prostate Cancer Treated with ¹⁷⁷Lu-PSMA617
2026 · Bayan Abu Alragheb, Nurlan Mammadzada, et al. · SSRN Electronic Journal
PDF
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2025 · Elizabeth Pan, Wanling Xie, et al.
Germline genetic variants in cancers of the urothelial tract and association with outcomes.
2025 · Kent Kamau, Lindsey Byrne, et al. · Journal of Clinical Oncology
Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra.
2024 · Kent Kamau, Lindsey Byrne, et al. · Journal of Clinical Oncology
Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2023 · Elizabeth Pan, Wanling Xie, et al.
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2023 · Elizabeth Pan, Wanling Xie, et al.
Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
2023 · Elizabeth Pan, Wanling Xie, et al.
Works count: 29
Citation count: 58
H-index: 2
I10-index: 1
Year
Topic
Type